Combination therapy of glucagon‐like peptide‐1 receptor agonists and insulin for patients who developed diabetes after partial pancreatectomy

Abstract

Aims/IntroductionIt is known that after pancreatectomy, patients experience hyposecretion of endogenous insulin and frequently develop diabetes. However, it has been unclear whether combination therapy with glucagon‐like peptide‐1 receptor agonists and basal insulin is effective for such patients. In the present study, we evaluated the efficacy and safety of combination therapy with long‐acting insulin glargine and the glucagon‐like peptide‐1 receptor agonist lixisenatide in patients who developed diabetes after pancreatectomy.Materials and MethodsJapanese patients who developed diabetes after pancreatectomy were eligible for this study. Participants were treated with combination therapy of glargine and lixisenatide for 12 weeks. Fasting and postprandial plasma glucose, C‐peptide immunoreactivity, glycated hemoglobin, bodyweight, visceral fat and subcutaneous fat were measured.ResultsAt 12 weeks after initiation of lixisenatide, glycated hemoglobin levels decreased from 8.46 ± 1.64% to 6.81 ± 1.15%. In addition, 1‐h postprandial plasma glucose and 2‐h postprandial plasma glucose levels significantly decreased from 222.9 ± 56.2 mg/dL to 125.1 ± 37.5 mg/dL (P < 0.001) and from 247.5 ± 56.8 mg/dL to 115.1 ± 29.0 mg/dL (P < 0.001), respectively. Neither hypoglycemia nor clinically relevant adverse events occurred during this study.ConclusionsThe present study shows that combination therapy with basal insulin and glucagon‐like peptide‐1 receptor agonists after partial pancreatectomy can be a useful therapeutic option for providing effective glycemic control with a reduced risk of hypoglycemia.

Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open‐label, multicenter study

“…The safety profile of lixisenatide was generally similar across the four background OAD groups, and consistent with the known safety profile of this class of GLP‐1 RAs. The safety data were also consistent with observations in previous international studies including Japanese patients, and Japan mono‐country studies in which lixisenatide was investigated either as monotherapy, or in combination with BI with or without an SU.…”

Effectiveness and safety of central pancreatectomy in benign or low-grade malignant pancreatic body lesions: a systematic review and meta-analysis

“…In summary, our study showed that most short-term complications of this procedure were significantly higher than those of DP. Although DP had a higher incidence of long-term postoperative endocrine and exocrine insufficiency, this was well controlled by oral hypoglycemic agents, insulin, and pancreatic enzymes 68 , 69 . The main objective of CP is to preserve more normal pancreatic tissues to better protect the secretory function of the pancreas.…”

Long‐term case study of a Wuzhishan miniature pig with diabetes

“…Unfortunately, it is impossible to measure the quality of human pancreatic islet beta‐cells in vivo. Models involving transplantation of human pancreas into immunodeficient animals also have some limitations and effects could be influenced by many exogenous factors . Despite few studies having found any evidence of β‐cell replication in adult humans, many xenograft models have shown newly activated human pancreatic islet cells in the grafts.…”